Pembrolizumab,Gemcitabine,Cisplatin
Merck
[]
sun april 16th 3:30 - 5:30 pm et #aacr23 | r. kate kelley, md will also present her study findings from 4:30 - 4:45 p.m. as part of clinical trials plenary session ctpl02 - hope for rare cancers: novel targeted and immunotherapy agents 
Championing basic science, clinical research, epidemiology/cancer control, and patient care.
Contact: cancer-communications@ucsf.edu